Headquartered in San Francisco, CA Fiscal year ends December NASDAQ: NKTR nektar.com
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. The company's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in Phase 3 trials for atopic dermatitis, with planned Phase 3 studies in alopecia areata and ongoing evaluation in Type 1 diabetes mellitus. Nektar's preclinical pipeline includes NKTR-0165 and NKTR-0166 (bivalent TNFR2 antibody and bispecific programs) and NKTR-422 (a modified hematopoietic colony stimulating factor protein). The company generates non-cash royalty revenue related to the sales of future royalties and is pre-commercialization, with no products currently on the market. Its current revenue is derived entirely from legacy royalty arrangements. The company trades on the Nasdaq under the ticker NKTR. Updated
Big pharma’s appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a…
Thursday's top analyst upgrades and downgrades included Airbnb, Alcon, Antero Midstream, Exact Sciences, GitLab, GlobalFoundries, Halozyme Therapeutics, Lumentum, Nektar Therapeutics, PayPal and Southern Copper.
Monday's additional top analyst upgrades and downgrades were on Coinbase Global, Global Blood Therapeutics, Grab, Leslie’s, Nektar Therapeutics, Park Hotels & Resorts, Rocket Companies and Roku.
Tuesday’s additional top analyst upgrades and downgrades included Dow, Estee Lauder, Magellan Midstream Partners, Nektar Therapeutics, Novo Nordisk, Rocket Companies, Sherwin-Williams, Steel Dynamics and Zoom Video Communications.
Monday’s additional top analyst upgrades and downgrades included Aptiv, BioCryst Pharmaceuticals, CSX, Gap, Nektar Therapeutics, Progressive, Peloton Interactive, Sirius XM and United Airlines.
Tuesday afternoon's top analyst upgrades and downgrades included Coupa Software, GoodRx, Mosaic and Nektar Therapeutics.
Wednesday afternoon's top analyst upgrades and downgrades included Bumble, Coupang, Foot Locker, Gap, Match, Nektar Therapeutics, Paychex, Signify Health and Stitch Fix.
Tuesday’s top analyst upgrades and downgrades included Bloomin' Brands, Boston Beer, Bumble, Goldman Sachs, Juniper Networks, Merck, Moderna, Petco Health, Southern Company, Spirit Airlines and Wells Fargo.
Tuesday's top analyst upgrades and downgrades included Airbnb, Canopy Growth, Continental Resources, DraftKings, Fisker, Moderna, Owens Corning, SunPower and Wayfair.
Friday’s top analyst upgrades and downgrades included American Tower, Best Buy, Beyond Meat, Editas Medicine, Freeport McMoRan, First Solar and UnitedHealth.
Monday’s top analyst upgrades and downgrades included GoDaddy, Groupon, Resmed, Salesforce, Shopify, Squarespace, Yelp, and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including BioNTech, Denali Therapeutics, Exelixis, Foot Locker and Hostess Brands.
Monday's top analyst upgrades and downgrades included Alphabet, Amazon.com, Amgen, Cerner, eBay, Gap, Nike, Nucor, Procter & Gamble, TJX and ViacomCBS.
Wednesday's top analyst upgrades, downgrades and initiations included Altria, Beyond Meat, Chevron, Chipotle Mexican Grill, Epizyme, FedEx, Home Depot, Mattel, Morgan Stanley, Oracle, Qualcomm and Target.
Monday's top analyst upgrades, downgrades and initiations included Aimmune Therapeutics, Amgen, Biogen, Chevron, CRISPR, Exxon Mobil, Nike, Snap, Uber, Ulta Beauty and Verizon.
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
The Wall Street consensus 12-month price target for NKTR is $141.40.
